This study shows that in this disease model antibodies that only block infection by neutralization (REGN3479), only have effector functions via signaling through FcγRIIIa (REGN3471), or combine both activities (REGN3470) show benefit in vivo when administered as a monotherapy. This evidence concerns the gene FCGR3A and infection.